- Keensight Capital’s investment will support BYG4lab to expand into new strategic areas in Europe and North America
- BYG4lab addresses both central lab and point of care testing, as well as all disciplines in the field of medical biology
- Keensight Capital will invest alongside the BYG4lab management team
Keensight Capital announced today that it has acquired a majority stake in BYG4lab. The investment will be made alongside BYG4lab’s management team.
BYG4lab headquartered in L’Union in France, addresses both central lab and point of care testing, as well as all disciplines in the field of medical biology – immunochemistry, haematology, molecular, and microbiology, among others. BYG4lab provides services that improve workflow management, make instrument integration more efficient, handle mega lab configuration, design personalised dashboards, maximise automatic validation and manage quality control.
Keensight Capital, a European growth buyout investor based in Paris, will aid BYG4lab to expand into new strategic areas in Europe and North America. The planned value creation for BYG4lab includes organic growth and acquisitions.
“We identified BYG4lab as a true international leading player in the healthtech space and have been impressed by its unique position in a market with strong value creation potential,” said Gregory Agez, partner at Keensight Capital. “We are delighted to partner with Cyril and the seasoned management team to support them in the next phase of BYG4lab’s growth.”
“Over the past 10 years, BYG4lab has become a leading player in its niche and is now ready to accelerate its growth by activating product diversification and geographic expansion,” said Cyril Verhille, BYG4lab CEO. “Keensight Capital’s investment is a significant signal of this new phase of our growth. Keensight team’s dual expertise in both technology and healthcare and its capacity to help us expand internationally will be great assets to bring the company to the next level.”